News Release 

Announcing the TCT 2019 late-breaking trials and science

Agenda available online

Cardiovascular Research Foundation

NEW YORK - August 8, 2019 - The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science presentations that will be reported at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place September 25 - 29, 2019 at The Moscone Center in San Francisco, California.

Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease, the leading cause of death in the world. The studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that demonstrate potential to treat or prevent cardiovascular disease.

Late-breaking trials and science will be presented in the Main Arena and highlighted during press conferences scheduled for Thursday, September 26; Friday, September 27; Saturday, September 28; and Sunday, September 29.

The complete agenda for TCT 2019 is available online: https://www.crf.org/tct/program/agenda/view-full-agenda. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty. Media are invited to attend TCT and can apply for media credentials online at: https://www.crf.org/tct/press/for-the-media/press-resources.

Thursday, September 26, 2019

Late-Breaking Trials

* TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing PCI

Roxana Mehran

* Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Stephan Windecker

* IDEAL-LM: A Randomized Trial of a Bioabsorbable Polymer DES With 4-Month DAPT vs a Durable Polymer DES With 12-Month DAPT in Patients With Left Main Coronary Artery Disease

Robert-Jan Van Geuns

Late-Breaking Science

* EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Ajay J. Kirtane

* MODEL U-SES: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated A Bioabsorbable Polymer-Based Sirolimus-Eluting Stent

Ken Kozuma

* AUGUSTUS ACS: A 2 × 2 Factorial Randomized Trial of Apixaban vs Warfarin and Aspirin vs Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Stephan Windecker

* TWILIGHT: Thrombogenicity Substudy: Impact of Ticagrelor Alone vs Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Usman Baber

Friday, September 27, 2019

Late-Breaking Trials

* SCOPE I: A Randomized Trial of the ACURATE Neo vs the SAPIEN 3 Bioprosthesis in Patients With Severe Aortic Stenosis

Jonas Lanz

* PORTICO: A Randomized Trial of Portico vs Commercially Available Transcatheter Aortic Valves in Patients With Severe Aortic Stenosis

Gregory P. Fontana

* PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

Raj Makkar

Late-Breaking Science

* Mitral Valve-in-Valve: One-Year Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprotheses

Mayra Guerrero

* STS/ACC TVT Registry: MitraClip Operator Volume-Outcome Relationship in the United States

Adnan K. Chhatriwalla

* STS Registry: Mitral Valve Surgery Institutional Volume-Outcome Relationship in the United States

Vinay Badhwar

* A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs Medical Treatment in Patients With Severe Tricuspid Regurgitation

Maurizio Taramasso

Saturday, September 28, 2019

Late-Breaking Trials

* COAPT: Three-Year Outcomes From a Randomized Trial of the MitraClip in Patients With Heart Failure and Severe Secondary Mitral Regurgitation

Michael J. Mack

* PARTNER 2A: Five-Year Outcomes From a Randomized Trial of Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Vinod H. Thourani

* EXCEL: Five-Year Outcomes From a Randomized Trial of PCI vs CABG in Patients With Left Main Coronary Artery Disease

Gregg W. Stone

Late-Breaking Science

* COMPLETE Timing Substudy: A Randomized Trial of Complete Staged Revascularization vs Infarct Artery PCI Alone in Patients With Acute Myocardial Infarction and Multivessel Disease - Importance of Revascularization Timing

David A. Wood

* EURO-CTO: Three-Year Outcomes From a Randomized Trial of PCI vs Medical Therapy in Patients With Chronic Total Coronary Occlusions

Gerald S. Werner

* MODERATO II: A Double-Blind Randomized Trial of Cardiac Neuromodulation Therapy in Patients With Hypertension

Karl-Heinz Kuck

* LEVANT: Five-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Kenneth Ouriel

Friday, September 29, 2019

Late-Breaking Trials

* COAPT: Cost-Effectiveness Analysis From a Randomized Trial of the MitraClip in Patients With Heart Failure and Severe Secondary Mitral Regurgitation

Suzanne J. Baron

* PARTNER 3: Health Status Outcomes From a Randomized Trial of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low Surgical Risk

Suzanne J. Baron

* REMEDIAL III: A Randomized Trial of Urine Flow Rate-Guided vs LVEDP-Guided Hydration in Patients at High Risk for Contrast Nephropathy

Carlo Briguori

Late-Breaking Science

* BIODEGRADE: A Large-Scale Randomized Trial of a Thin-Strut Bioabsorbable Polymer-Based DES vs a Thick-Strut Bioabsorbable Polymer-Based DES in an All-Comers Population With Coronary Artery Disease

IN-HO CHAE

* BLADE-PCI: A Randomized Trial of Liposomal Alendronate in Patients With Diabetes Undergoing PCI

Philippe Genereux

* FORZA: A Randomized Trial of Fractional Flow Reserve vs Optical Coherence Tomography to Guide Revascularization of Intermediate Coronary Stenoses

Francesco Burzotta

* IVUS-XPL: Five-Year Outcomes From a Randomized Trial of Intravascular Ultrasound-Guided vs Angiography-Guided PCI of Long Coronary Lesions

Myeong-Ki Hong

Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.

###

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is one of the world's leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 31st year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. TCT also includes interactive training pavilions where clinicians can gain vital skills to apply immediately to their practices.

For more information, visit http://www.crf.org and http://www.tctconference.com.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.